News
-
-
-
COMMUNIQUÉ DE PRESSE
Asthma and Allergy Drug Development Is Failing Too Often--A Translational Reset Is Needed: HKEY-AIRx™1.0
HKeyBio introduces HKEY-AIRx™1.0, a preclinical strategy to enhance asthma and allergy drug development success by aligning disease endotypes, patient heterogeneity, and translational endpoints